1 – 7 of 7
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma
(
- Contribution to journal › Article
- 2015
-
Mark
Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
(
- Contribution to journal › Article
- 2009
-
Mark
Impaired Stem Cell Mobilization by Fludarabine in MM: Results from a Randomized Phase II Trial
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
A Randomised Placebo Controlled Study With Melphalan/Prednisone Vs Melphalan/Prednisone/Thalidomide: Quality Of Life And Toxicity
2008) 13th Congress of the European-Hematology-Association In Haematologica-The Hematology Journal 93. p.0209-0209(
- Contribution to journal › Published meeting abstract
- 2007
-
Mark
An internadional field study of the reliability and validity of a disease-specfic questionnanire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma
(
- Contribution to journal › Article
- 2004
-
Mark
Low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma
(
- Contribution to journal › Article
-
Mark
Early response predicts thalidomide efficiency in patients with advanced multiple myeloma
(
- Contribution to journal › Article